703 related articles for article (PubMed ID: 9272507)
1. Molecular biology of the long QT syndrome: impact on management.
Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
[TBL] [Abstract][Full Text] [Related]
2. A molecular basis for the therapy of the long QT syndrome.
Priori SG; Napolitano C; Schwartz PJ
Arch Mal Coeur Vaiss; 1996 Sep; 89(9):1185-7. PubMed ID: 8952843
[TBL] [Abstract][Full Text] [Related]
3. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
Schwartz PJ; Priori SG; Locati EH; Napolitano C; Cantù F; Towbin JA; Keating MT; Hammoude H; Brown AM; Chen LS; Colatsky TJ
Circulation; 1995 Dec; 92(12):3381-6. PubMed ID: 8521555
[TBL] [Abstract][Full Text] [Related]
4. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
Priori SG; Cantù F; Schwartz PJ
Schweiz Med Wochenschr; 1996 Oct; 126(41):1727-31. PubMed ID: 8893413
[TBL] [Abstract][Full Text] [Related]
5. Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome.
Priori SG; Napolitano C; Cantù F; Brown AM; Schwartz PJ
Circ Res; 1996 Jun; 78(6):1009-15. PubMed ID: 8635231
[TBL] [Abstract][Full Text] [Related]
6. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome.
Shimizu W; Antzelevitch C
J Am Coll Cardiol; 2000 Mar; 35(3):778-86. PubMed ID: 10716483
[TBL] [Abstract][Full Text] [Related]
8. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome.
Shimizu W; Antzelevitch C
Circulation; 1997 Sep; 96(6):2038-47. PubMed ID: 9323097
[TBL] [Abstract][Full Text] [Related]
9. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome.
Bos JM; Crotti L; Rohatgi RK; Castelletti S; Dagradi F; Schwartz PJ; Ackerman MJ
Circ Arrhythm Electrophysiol; 2019 May; 12(5):e007280. PubMed ID: 31006312
[TBL] [Abstract][Full Text] [Related]
10. Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome.
Shimizu W; Antzelevitch C
Circulation; 2000 Aug; 102(6):706-12. PubMed ID: 10931813
[TBL] [Abstract][Full Text] [Related]
11. [Molecular genetics in the hereditary form of long QT syndrome].
Georgijević Milić L
Med Pregl; 2000; 53(1-2):51-4. PubMed ID: 10953551
[TBL] [Abstract][Full Text] [Related]
12. Sodium channel blockers in the management of long QT syndrome types 3 and 2: A system review and meta-analysis.
Yang Y; Lv TT; Li SY; Zhang P
J Cardiovasc Electrophysiol; 2021 Nov; 32(11):3057-3067. PubMed ID: 34427958
[TBL] [Abstract][Full Text] [Related]
13. Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome.
Shimizu W; Antzelevitch C
J Electrocardiol; 1999; 32 Suppl():177-84. PubMed ID: 10688323
[TBL] [Abstract][Full Text] [Related]
14. Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects.
Swan H; Viitasalo M; Piippo K; Laitinen P; Kontula K; Toivonen L
J Am Coll Cardiol; 1999 Sep; 34(3):823-9. PubMed ID: 10483966
[TBL] [Abstract][Full Text] [Related]
15. Genetics, molecular mechanisms and management of long QT syndrome.
Wang Q; Chen Q; Towbin JA
Ann Med; 1998 Feb; 30(1):58-65. PubMed ID: 9556090
[TBL] [Abstract][Full Text] [Related]
16. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype.
Zareba W; Moss AJ; Locati EH; Lehmann MH; Peterson DR; Hall WJ; Schwartz PJ; Vincent GM; Priori SG; Benhorin J; Towbin JA; Robinson JL; Andrews ML; Napolitano C; Timothy K; Zhang L; Medina A;
J Am Coll Cardiol; 2003 Jul; 42(1):103-9. PubMed ID: 12849668
[TBL] [Abstract][Full Text] [Related]
17. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes.
Shimizu W; Antzelevitch C
Circulation; 1998 Nov; 98(21):2314-22. PubMed ID: 9826320
[TBL] [Abstract][Full Text] [Related]
18. Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome.
Shimizu W; Aiba T; Antzelevitch C
Curr Pharm Des; 2005; 11(12):1561-72. PubMed ID: 15892662
[TBL] [Abstract][Full Text] [Related]
19. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers.
Priori SG; Napolitano C; Schwartz PJ; Grillo M; Bloise R; Ronchetti E; Moncalvo C; Tulipani C; Veia A; Bottelli G; Nastoli J
JAMA; 2004 Sep; 292(11):1341-4. PubMed ID: 15367556
[TBL] [Abstract][Full Text] [Related]
20. The long QT syndromes: genetic basis and clinical implications.
Chiang CE; Roden DM
J Am Coll Cardiol; 2000 Jul; 36(1):1-12. PubMed ID: 10898405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
